标题
Immunotherapy for breast cancer: past, present, and future
作者
关键词
Immunotherapy, Breast cancer, Review, Checkpoint inhibitor, Biomarkers, Clinical trials
出版物
CANCER AND METASTASIS REVIEWS
Volume 35, Issue 4, Pages 525-546
出版商
Springer Nature
发表日期
2016-12-02
DOI
10.1007/s10555-016-9654-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Abstract P2-11-09: A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data
- (2016) S-C Tang et al. CANCER RESEARCH
- Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
- (2016) S Adams et al. CANCER RESEARCH
- Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028
- (2016) HS Rugo et al. CANCER RESEARCH
- Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial
- (2016) LY Dirix et al. CANCER RESEARCH
- Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
- (2015) Rita Nanda et al. CANCER RESEARCH
- Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer
- (2015) Leisha A Emens et al. CANCER RESEARCH
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab
- (2015) Xiao Ni et al. OncoImmunology
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
- (2014) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Abstract P5-16-02: Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine
- (2014) TJ Vreeland et al. CANCER RESEARCH
- Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
- (2014) T. T. Junttila et al. CANCER RESEARCH
- Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
- (2014) Y. Saenger et al. CLINICAL CANCER RESEARCH
- Bispecific antibody platforms for cancer immunotherapy
- (2014) Roeland Lameris et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines
- (2014) Elham Mohit et al. Expert Review of Clinical Immunology
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies — Impact of effector cells
- (2014) Shan Chung et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
- (2014) Michael A Postow et al. Journal of Translational Medicine
- Harnessing the immune system for the treatment of breast cancer
- (2014) Xinguo Jiang Journal of Zhejiang University-SCIENCE B
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Mitigating the toxic effects of anticancer immunotherapy
- (2014) Tara C. Gangadhar et al. Nature Reviews Clinical Oncology
- IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis
- (2014) M. T. Isla Larrain et al. TUMOR BIOLOGY
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
- (2014) G. Chen et al. Cancer Immunology Research
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Inhibitory Fc RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity
- (2013) A. T. Vaughan et al. BLOOD
- Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
- (2013) Ursula Wiedermann et al. BREAST CANCER RESEARCH AND TREATMENT
- Myeloid-derived suppressor cells in breast cancer
- (2013) Joseph Markowitz et al. BREAST CANCER RESEARCH AND TREATMENT
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- The role of intratumoral and systemic IL-6 in breast cancer
- (2013) Christine Dethlefsen et al. BREAST CANCER RESEARCH AND TREATMENT
- Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice
- (2013) Yan Ge et al. CANCER LETTERS
- Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
- (2013) Xiaoqiang Tang CANCER LETTERS
- Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
- (2013) Z. C. Hartman et al. CANCER RESEARCH
- Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer
- (2013) Yuan Huang et al. CURRENT DRUG TARGETS
- Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
- (2013) Baris Boyraz et al. CURRENT MEDICAL RESEARCH AND OPINION
- The role of tumor-associated macrophages in breast cancer progression
- (2013) ELIAS OBEID et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
- (2013) J. Yu et al. JOURNAL OF IMMUNOLOGY
- Interleukin-8 in Breast Cancer Progression
- (2013) Nataša Todorović-Raković et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
- (2013) Vafa Shahabi et al. Journal of Translational Medicine
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast Cancer
- (2013) Michael S. Hwang et al. PLoS One
- Hydrazinocurcumin Encapsuled Nanoparticles “Re-Educate” Tumor-Associated Macrophages and Exhibit Anti-Tumor Effects on Breast Cancer Following STAT3 Suppression
- (2013) Xiwen Zhang et al. PLoS One
- Introducing the society for immunotherapy of cancer’s new journal: journal for immunoTherapy of cancer
- (2013) Pedro J Romero et al. Journal for ImmunoTherapy of Cancer
- Pertuzumab: new hope for patients with HER2-positive breast cancer
- (2012) M. Capelan et al. ANNALS OF ONCOLOGY
- Advances in bispecific biotherapeutics for the treatment of cancer
- (2012) Chad May et al. BIOCHEMICAL PHARMACOLOGY
- Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
- (2012) R Y Tsang et al. BRITISH JOURNAL OF CANCER
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- Abstract 654: MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells
- (2012) Shinji K. Oyama et al. CANCER RESEARCH
- P1-13-01: An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence.
- (2012) DF Hale et al. CANCER RESEARCH
- Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
- (2012) I. Verbrugge et al. CANCER RESEARCH
- Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
- (2012) Leisha A Emens Expert Review of Anticancer Therapy
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- The GP2 peptide: A HER2/neu-based breast cancer vaccine
- (2012) Kevin S. Clive et al. JOURNAL OF SURGICAL ONCOLOGY
- Therapeutic Cancer Vaccines: Current Status and Moving Forward
- (2012) J. Schlom JNCI-Journal of the National Cancer Institute
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
- (2012) Vivian L. Weiss et al. PLoS One
- Tumor Associated Macrophage × Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer
- (2012) Jingxian Ding et al. PLoS One
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
- (2012) A. J. Rech et al. Science Translational Medicine
- Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
- (2012) Jian Yang et al. STEM CELLS
- Differential macrophage programming in the tumor microenvironment
- (2012) Brian Ruffell et al. TRENDS IN IMMUNOLOGY
- Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer
- (2011) A. J. Montero et al. BREAST CANCER RESEARCH AND TREATMENT
- Dual HER2-targeted approaches in HER2-positive breast cancer
- (2011) Eugene R. Ahn et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients
- (2011) Elizabeth A. Mittendorf et al. CANCER
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- A Th1 cytokine–enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells
- (2011) Archana Thakur et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
- (2011) P. B. Olkhanud et al. CANCER RESEARCH
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
- (2011) J. Godin-Ethier et al. CLINICAL CANCER RESEARCH
- Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells
- (2011) Scott K. Pruitt et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- AE37: a novel T-cell-eliciting vaccine for breast cancer
- (2011) Alan K Sears et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis
- (2011) Catherine E. Steding et al. IMMUNOLOGY
- Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions
- (2011) Damya Laoui et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures
- (2011) Yawei Yuan INTERNATIONAL JOURNAL OF ONCOLOGY
- Breast cancer stem cells, cytokine networks, and the tumor microenvironment
- (2011) Hasan Korkaya et al. JOURNAL OF CLINICAL INVESTIGATION
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating macrophages and clinical outcome in breast cancer
- (2011) S M A Mahmoud et al. JOURNAL OF CLINICAL PATHOLOGY
- Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells
- (2011) Jingyan Sun et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
- (2011) Sylvain Ladoire et al. JOURNAL OF PATHOLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
- (2011) Vincenzo Cerullo et al. MOLECULAR THERAPY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
- (2011) Wenjin Yin et al. PLoS One
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted therapy in breast cancer: what's new?
- (2011) L Fang et al. SWISS MEDICAL WEEKLY
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome
- (2010) Michael J. Campbell et al. BREAST CANCER RESEARCH AND TREATMENT
- Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine
- (2010) Jarrod P. Holmes et al. CANCER
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- IDO inhibits T-cell function through suppressing Vav1 expression and activation
- (2010) Runmei Li et al. CANCER BIOLOGY & THERAPY
- Anti-HER2 vaccines: new prospects for breast cancer therapy
- (2010) Maha Zohra Ladjemi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antiestrogens Induce Transforming Growth Factor -Mediated Immunosuppression in Breast Cancer
- (2010) C. M. Joffroy et al. CANCER RESEARCH
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Cell Death Mechanisms Induced by Cytotoxic Lymphocytes
- (2010) L Chávez-Galán et al. Cellular & Molecular Immunology
- Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
- (2010) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide
- (2010) Jeremy D. Gates et al. VACCINE
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
- (2009) Ursula Wiedermann et al. BREAST CANCER RESEARCH AND TREATMENT
- Arginase: an emerging key player in the mammalian immune system
- (2009) Markus Munder BRITISH JOURNAL OF PHARMACOLOGY
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Results of the first phase 1 clinical trial of the HER-2/neupeptide (GP2) vaccine in disease-free breast cancer patients
- (2009) Mark G. Carmichael et al. CANCER
- The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
- (2009) M. Jager et al. CANCER RESEARCH
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
- (2009) M. Gobert et al. CANCER RESEARCH
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
- (2009) Emmanuelle Charafe-Jauffret et al. CANCER RESEARCH
- An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation
- (2009) Dimitrios Iliopoulos et al. CELL
- The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2009) L. C. Benavides et al. CLINICAL CANCER RESEARCH
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
- (2009) Pravin T.P. Kaumaya et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
- (2009) Mary L. Disis et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
- (2009) J. Bostrom et al. SCIENCE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
- (2008) M K Robinson et al. BRITISH JOURNAL OF CANCER
- Optimal dose and schedule of an HER-2/neu(E75) peptide vaccine to prevent breast cancer recurrence
- (2008) Jarrod P. Holmes et al. CANCER
- Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells
- (2008) Johanna K. Morales et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
- (2008) C. Marcela Diaz-Montero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2008) G. E. Peoples et al. CLINICAL CANCER RESEARCH
- Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine
- (2008) Jarrod P. Holmes et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of the Cancer Stem-Cell Hypothesis for Breast Cancer Prevention and Therapy
- (2008) Madhuri Kakarala et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
- Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target
- (2008) Sandra D Bohling et al. MODERN PATHOLOGY
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started